JP5816965B2 - Ｅｃｔ２ペプチドおよびそれを含むワクチン - Google Patents

Ｅｃｔ２ペプチドおよびそれを含むワクチン Download PDF

Info

Publication number
JP5816965B2
JP5816965B2 JP2012543839A JP2012543839A JP5816965B2 JP 5816965 B2 JP5816965 B2 JP 5816965B2 JP 2012543839 A JP2012543839 A JP 2012543839A JP 2012543839 A JP2012543839 A JP 2012543839A JP 5816965 B2 JP5816965 B2 JP 5816965B2
Authority
JP
Japan
Prior art keywords
peptide
cancer
ect2
peptides
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012543839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523082A5 (enExample
JP2013523082A (ja
Inventor
中村　祐輔
祐輔 中村
卓也 角田
卓也 角田
龍司 大沢
龍司 大沢
祥子 吉村
祥子 吉村
朝久 渡辺
朝久 渡辺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2013523082A publication Critical patent/JP2013523082A/ja
Publication of JP2013523082A5 publication Critical patent/JP2013523082A5/ja
Application granted granted Critical
Publication of JP5816965B2 publication Critical patent/JP5816965B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012543839A 2010-04-02 2011-03-30 Ｅｃｔ２ペプチドおよびそれを含むワクチン Active JP5816965B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32057710P 2010-04-02 2010-04-02
US61/320,577 2010-04-02
PCT/JP2011/001909 WO2011122022A1 (en) 2010-04-02 2011-03-30 Ect2 peptides and vaccines including the same

Publications (3)

Publication Number Publication Date
JP2013523082A JP2013523082A (ja) 2013-06-17
JP2013523082A5 JP2013523082A5 (enExample) 2014-05-15
JP5816965B2 true JP5816965B2 (ja) 2015-11-18

Family

ID=44711777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012543839A Active JP5816965B2 (ja) 2010-04-02 2011-03-30 Ｅｃｔ２ペプチドおよびそれを含むワクチン

Country Status (20)

Country Link
US (1) US8951975B2 (enExample)
EP (1) EP2553096B1 (enExample)
JP (1) JP5816965B2 (enExample)
KR (1) KR101863557B1 (enExample)
CN (1) CN102939379B (enExample)
AR (1) AR081065A1 (enExample)
AU (1) AU2011233401B2 (enExample)
BR (1) BR112012024997B1 (enExample)
CA (1) CA2795318C (enExample)
CO (1) CO6571869A2 (enExample)
DK (1) DK2553096T3 (enExample)
EA (1) EA027940B1 (enExample)
ES (1) ES2655437T3 (enExample)
IL (1) IL222057A (enExample)
MX (1) MX342000B (enExample)
NZ (1) NZ603379A (enExample)
SG (1) SG184165A1 (enExample)
TW (2) TWI538685B (enExample)
WO (1) WO2011122022A1 (enExample)
ZA (1) ZA201207342B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PH12022551111A1 (en) 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
EP1332153A4 (en) * 2000-10-12 2006-01-11 Exelixis Inc HUMAN ECT2 AND METHOD OF USE THEREOF
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7227007B2 (en) * 2000-12-28 2007-06-05 Asahi Kasei Pharma Corporation NF-κB activating gene
EP2336167B1 (en) 2001-03-14 2019-05-29 Dako Denmark A/S MHC molecule constructs and their uses for diagnosis and therapy
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2002096943A1 (en) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Stat6-activating genes
US20030092616A1 (en) 2001-05-25 2003-05-15 Akio Matsuda STAT6 activation gene
WO2002099062A2 (en) 2001-06-04 2002-12-12 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
CA2447935A1 (en) * 2001-06-04 2002-12-12 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4614952B2 (ja) 2003-08-20 2011-01-19 オンコセラピー・サイエンス株式会社 腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２）
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
EP1907582B1 (en) 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
EP2305811A1 (en) 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
CN101432022A (zh) * 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗-EphA4抗体效应物作用损伤细胞的方法
AU2007311946A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
JP5378795B2 (ja) 2006-10-20 2013-12-25 中外製薬株式会社 抗ｈｂ−ｅｇｆ抗体を有効成分として含む医薬組成物
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
WO2010007791A1 (en) * 2008-07-16 2010-01-21 Oncotherapy Science, Inc. Ect2 oncogene as a therapeutic target and prognostic indicator for lung and esophageal cancer
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
DK2553096T3 (en) 2018-01-15
IL222057A (en) 2017-12-31
TWI538685B (zh) 2016-06-21
SG184165A1 (en) 2012-10-30
TW201138803A (en) 2011-11-16
EP2553096A1 (en) 2013-02-06
JP2013523082A (ja) 2013-06-17
NZ603379A (en) 2014-09-26
BR112012024997B1 (pt) 2022-03-22
KR101863557B1 (ko) 2018-06-01
EP2553096B1 (en) 2017-11-22
CO6571869A2 (es) 2012-11-30
ES2655437T3 (es) 2018-02-20
MX342000B (es) 2016-09-09
AR081065A1 (es) 2012-06-06
BR112012024997A2 (pt) 2017-05-23
US8951975B2 (en) 2015-02-10
CA2795318A1 (en) 2011-10-06
CA2795318C (en) 2018-11-13
EA027940B1 (ru) 2017-09-29
KR20130033367A (ko) 2013-04-03
EP2553096A4 (en) 2013-11-13
WO2011122022A1 (en) 2011-10-06
TW201627003A (zh) 2016-08-01
CN102939379A (zh) 2013-02-20
ZA201207342B (en) 2013-06-26
US20130095128A1 (en) 2013-04-18
AU2011233401A1 (en) 2012-10-25
AU2011233401B2 (en) 2015-03-26
CN102939379B (zh) 2016-08-03
EA201291004A1 (ru) 2013-04-30
MX2012011385A (es) 2013-12-16

Similar Documents

Publication Publication Date Title
JP5799394B2 (ja) Ｎｅｉｌ３ペプチドおよびそれを含むワクチン
JP5884104B2 (ja) 改変ｍｅｌｋペプチドおよびそれを含むワクチン
JP2013523084A (ja) Ｃｄｃａ５ペプチドおよびそれを含むワクチン
JP5564730B2 (ja) Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
JP2014519311A (ja) Ｓｅｍａ５ｂペプチドおよびそれを含むワクチン
JP2016222676A (ja) Ｔｏｍｍ３４ペプチドおよびそれを含むワクチン
US9896492B2 (en) HJURP peptides and vaccines including the same
JP5786178B2 (ja) Ｔｔｋペプチドおよびそれを含むワクチン
JP2012519470A (ja) Ｖａｎｇｌ１ペプチドおよびそれを含むワクチン
US8951975B2 (en) ECT2 peptides and vaccines including the same
WO2012032764A1 (en) Ttll4 peptides and vaccines containing the same
JP2013513549A (ja) Ｔｍｅｍ２２ペプチドおよびそれを含むワクチン
JP2013512659A (ja) Ｍｙｂｌ２ペプチドおよびそれを含むワクチン
JP2016502499A (ja) Ｓｅｍａ５ｂペプチドおよびそれを含むワクチン
JP2014500001A (ja) Ｃ１８ｏｒｆ５４ペプチドおよびそれを含むワクチン
JP2014504146A (ja) Ｗｄｈｄ１ペプチドおよびそれを含むワクチン
JP2013523083A (ja) Ｃｌｕａｐ１ペプチドおよびそれを含むワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140325

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150902

R150 Certificate of patent or registration of utility model

Ref document number: 5816965

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250